398 related articles for article (PubMed ID: 14610480)
1. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.
Wachholz PA; Soni NK; Till SJ; Durham SR
J Allergy Clin Immunol; 2003 Nov; 112(5):915-22. PubMed ID: 14610480
[TBL] [Abstract][Full Text] [Related]
2. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.
James LK; Bowen H; Calvert RA; Dodev TS; Shamji MH; Beavil AJ; McDonnell JM; Durham SR; Gould HJ
J Allergy Clin Immunol; 2012 Sep; 130(3):663-670.e3. PubMed ID: 22583928
[TBL] [Abstract][Full Text] [Related]
3. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.
Mothes N; Heinzkill M; Drachenberg KJ; Sperr WR; Krauth MT; Majlesi Y; Semper H; Valent P; Niederberger V; Kraft D; Valenta R
Clin Exp Allergy; 2003 Sep; 33(9):1198-208. PubMed ID: 12956739
[TBL] [Abstract][Full Text] [Related]
4. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
5. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.
James LK; Shamji MH; Walker SM; Wilson DR; Wachholz PA; Francis JN; Jacobson MR; Kimber I; Till SJ; Durham SR
J Allergy Clin Immunol; 2011 Feb; 127(2):509-516.e1-5. PubMed ID: 21281875
[TBL] [Abstract][Full Text] [Related]
6. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.
Shamji MH; Wilcock LK; Wachholz PA; Dearman RJ; Kimber I; Wurtzen PA; Larché M; Durham SR; Francis JN
J Immunol Methods; 2006 Dec; 317(1-2):71-9. PubMed ID: 17070537
[TBL] [Abstract][Full Text] [Related]
7. A Recombinant Fragment of Human Surfactant Protein D Suppresses Basophil Activation and T-Helper Type 2 and B-Cell Responses in Grass Pollen-induced Allergic Inflammation.
Qaseem AS; Singh I; Pathan AA; Layhadi JA; Parkin R; Alexandra F; Durham SR; Kishore U; Shamji MH
Am J Respir Crit Care Med; 2017 Dec; 196(12):1526-1534. PubMed ID: 28915062
[TBL] [Abstract][Full Text] [Related]
8. Recombinant pollen allergens from Dactylis glomerata: preliminary evidence that human IgE cross-reactivity between Dac g II and Lol p I/II is increased following grass pollen immunotherapy.
Roberts AM; Van Ree R; Cardy SM; Bevan LJ; Walker MR
Immunology; 1992 Jul; 76(3):389-96. PubMed ID: 1526648
[TBL] [Abstract][Full Text] [Related]
9. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
11. Anti-idiotype antibodies could explain inhibition of allergen-IgE binding to B cells after grass pollen immunotherapy.
Simon MR
J Allergy Clin Immunol; 2004 Jun; 113(6):1225; author reply 1225-6. PubMed ID: 15214366
[No Abstract] [Full Text] [Related]
12. IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors.
Meulenbroek LA; de Jong RJ; den Hartog Jager CF; Monsuur HN; Wouters D; Nauta AJ; Knippels LM; van Neerven RJ; Ruiter B; Leusen JH; Hack CE; Bruijnzeel-Koomen CA; Knulst AC; Garssen J; van Hoffen E
J Immunol; 2013 Oct; 191(7):3526-33. PubMed ID: 23997216
[TBL] [Abstract][Full Text] [Related]
13. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
14. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy.
Aberer W; Hawranek T; Reider N; Schuster C; Sturm G; Kränke B
J Investig Allergol Clin Immunol; 2007; 17(3):131-6. PubMed ID: 17583098
[TBL] [Abstract][Full Text] [Related]
18. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
19. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.
Varga EM; Francis JN; Zach MS; Klunker S; Aberer W; Durham SR
Clin Exp Allergy; 2009 Sep; 39(9):1353-7. PubMed ID: 19538349
[TBL] [Abstract][Full Text] [Related]
20. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE.
Niederberger V; Laffer S; Fröschl R; Kraft D; Rumpold H; Kapiotis S; Valenta R; Spitzauer S
J Allergy Clin Immunol; 1998 Feb; 101(2 Pt 1):258-64. PubMed ID: 9500760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
